These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 23626542)

  • 1. Eruptive Nevi Mimicking Wart-Like Lesions under Selective BRAF Inhibition in a 37-Year-Old Female Melanoma Patient.
    Schmitt L; Schumann T; Inhoff O; Löser C; Rebel M; Dippel E
    Case Rep Dermatol; 2013 Jan; 5(1):69-72. PubMed ID: 23626542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Appearance of New Vemurafenib-associated Melanocytic Nevi on Normal-appearing Skin: Case Series and a Review of Changing or New Pigmented Lesions in Patients with Metastatic Malignant Melanoma After Initiating Treatment with Vemurafenib.
    Cohen PR; Bedikian AY; Kim KB
    J Clin Aesthet Dermatol; 2013 May; 6(5):27-37. PubMed ID: 23710269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NRAS Q61R and BRAF G466A mutations in atypical melanocytic lesions newly arising in advanced melanoma patients treated with vemurafenib.
    Parekh V; Sobanko J; Miller CJ; Karakousis G; Xu W; Letrero R; Elenitsas R; Xu X; Elder DE; Amaravadi R; Schuchter LM; Nathanson KL; Wilson MA; Chu EY
    J Cutan Pathol; 2019 Mar; 46(3):190-194. PubMed ID: 30552700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.
    Peters S; Bouchaab H; Zimmerman S; Bucher M; Gaide O; Letovanec I; Homicsko K; Michielin O
    Melanoma Res; 2014 Oct; 24(5):496-500. PubMed ID: 25185693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eruptive Junctional Nevi Appearing During Langerhans Cell Histiocytosis Treatment.
    Mendonça-Sanches M; Rolim I; Costa-Rosa J; Caldas G; Moura C
    Eur J Case Rep Intern Med; 2019; 6(6):001088. PubMed ID: 31293989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of melanocytic nevi under vemurafenib, followed by combination therapy with dabrafenib and trametinib for metastatic melanoma.
    Giurcaneanu C; Nitipir C; Popa LG; Forsea AM; Popescu I; Bumbacea RS
    Acta Dermatovenerol Croat; 2015; 23(2):114-21. PubMed ID: 26228819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.
    Chu EY; Wanat KA; Miller CJ; Amaravadi RK; Fecher LA; Brose MS; McGettigan S; Giles LR; Schuchter LM; Seykora JT; Rosenbach M
    J Am Acad Dermatol; 2012 Dec; 67(6):1265-72. PubMed ID: 22609219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involution of eruptive melanocytic nevi on combination BRAF and MEK inhibitor therapy.
    Chen FW; Tseng D; Reddy S; Daud AI; Swetter SM
    JAMA Dermatol; 2014 Nov; 150(11):1209-12. PubMed ID: 25142409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eruptive Melanocytic Nevi Secondary to Encorafenib for BRAF Mutant Metastatic Colorectal Cancer.
    Meneguzzo A; Lazzarotto A; Alaibac M
    In Vivo; 2020; 34(1):441-445. PubMed ID: 31882511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition.
    Zimmer L; Hillen U; Livingstone E; Lacouture ME; Busam K; Carvajal RD; Egberts F; Hauschild A; Kashani-Sabet M; Goldinger SM; Dummer R; Long GV; McArthur G; Scherag A; Sucker A; Schadendorf D
    J Clin Oncol; 2012 Jul; 30(19):2375-83. PubMed ID: 22614973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.
    Sufficool KE; Hepper DM; Linette GP; Hurst EA; Lu D; Lind AC; Cornelius LA
    J Cutan Pathol; 2014 Jul; 41(7):568-75. PubMed ID: 24641301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of BRAF V600 mutation in melanoma.
    Ascierto PA; Kirkwood JM; Grob JJ; Simeone E; Grimaldi AM; Maio M; Palmieri G; Testori A; Marincola FM; Mozzillo N
    J Transl Med; 2012 Jul; 10():85. PubMed ID: 22554099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic changes in nevi of a patient with melanoma treated with vemurafenib: importance of sequential dermoscopy.
    Haenssle HA; Kraus SL; Brehmer F; Kretschmer L; Völker B; Asper H; Kapp A; Gutzmer R
    Arch Dermatol; 2012 Oct; 148(10):1183-5. PubMed ID: 22911096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of BRAF mutations in eruptive melanocytic nevi: new insights into melanomagenesis?
    John JK; Smalley KS
    Expert Rev Anticancer Ther; 2011 May; 11(5):711-4. PubMed ID: 21554046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin.
    Uribe P; Wistuba II; González S
    Am J Dermatopathol; 2003 Oct; 25(5):365-70. PubMed ID: 14501284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients.
    Boussemart L; Routier E; Mateus C; Opletalova K; Sebille G; Kamsu-Kom N; Thomas M; Vagner S; Favre M; Tomasic G; Wechsler J; Lacroix L; Robert C
    Ann Oncol; 2013 Jun; 24(6):1691-7. PubMed ID: 23406731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete regression of primary melanoma associated with nevi involution under BRAF inhibitors: A case report and review of the literature.
    Grigore LE; Ungureanu L; Bejinariu N; Seceac C; Vasilovici A; Senila SC; Candrea E; Fechete O; Cosgarea R
    Oncol Lett; 2019 May; 17(5):4176-4182. PubMed ID: 30944613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant vemurafenib in resected, BRAF
    Maio M; Lewis K; Demidov L; Mandalà M; Bondarenko I; Ascierto PA; Herbert C; Mackiewicz A; Rutkowski P; Guminski A; Goodman GR; Simmons B; Ye C; Yan Y; Schadendorf D;
    Lancet Oncol; 2018 Apr; 19(4):510-520. PubMed ID: 29477665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.
    Mudaliar K; Tetzlaff MT; Duvic M; Ciurea A; Hymes S; Milton DR; Tsai KY; Prieto VG; Torres-Cabala CA; Curry JL
    Hum Pathol; 2016 Apr; 50():79-89. PubMed ID: 26997441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of vemurafenib-induced keratosis pilaris-like eruption.
    Wang CM; Fleming KF; Hsu S
    Dermatol Online J; 2012 Apr; 18(4):7. PubMed ID: 22559022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.